The release tests a licensed biologic has to pass

No lot leaves before the tests are finished

The opening rule of the general biological products standards is one paragraph and it sets the whole frame. No lot of any licensed product shall be released by the manufacturer prior to the completion of tests for conformity with standards applicable to such product. Each applicable test must be made on each lot after completion of all processes of manufacture which may affect compliance with the standard the test applies to.

The same paragraph then addresses the question every testing regime eventually faces: what happens to a result nobody likes. The results of all tests performed shall be considered in determining whether the test results meet the test objective, except that a test result may be disregarded when it is established that the test is invalid due to causes unrelated to the product.

Read carefully, that is a narrow door. All results count. A result may be set aside only where the test itself is established as invalid, and only for a cause unrelated to the product. Establishing is an active verb; disliking the number is not a cause.

These standards apply to licensed biological products — products that went through a biologics licence application and came out the other side licensed. That matters for scope. Most compounds discussed on this site are not licensed biological products, and part 610 does not reach them. What the part offers a reader is not a badge to look for but a definition of what a fully regulated release test regime actually consists of, against which any other assurance can be measured.

One further provision closes off product-by-product improvisation. Licensed products may not be combined with other licensed products, whether therapeutic, prophylactic or diagnostic, except where a licence is obtained for the combined product — and may not be combined with non-licensable substances except where a licence is obtained for the combination.

Four words with legal definitions

The definitions section for biological products defines the vocabulary the release tests use, and each definition is narrower than its everyday meaning.

Standards means specifications and procedures applicable to an establishment or to the manufacture or release of products, prescribed in the regulations or established in the biologics licence application, designed to insure the continued safety, purity and potency of such products. And continued, as applied to safety, purity and potency, is interpreted to apply to the dating period. The assurance is not a moment; it is a window.

Safety means the relative freedom from harmful effect to persons affected, directly or indirectly, by a product when prudently administered, taking into consideration the character of the product in relation to the condition of the recipient at the time. Every clause in that sentence is a qualifier. Relative, not absolute. When prudently administered. Taking the recipient's condition into account.

Sterility is interpreted to mean freedom from viable contaminating microorganisms, as determined by the tests conducted under the sterility section. The definition points at a test rather than at a state.

Purity means relative freedom from extraneous matter in the finished product, whether or not harmful to the recipient or deleterious to the product. It includes but is not limited to relative freedom from residual moisture or other volatile substances and pyrogenic substances. Note the phrase whether or not harmful: matter that does no damage still counts against purity.

Potency is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through administration of the product in the manner intended, to effect a given result. And the potency section makes the corresponding demand: tests for potency shall consist of either in vitro or in vivo tests, or both, specifically designed for each product so as to indicate its potency in a manner adequate to satisfy that definition. Potency is not a purity figure. It is a demonstrated ability to produce an effect.

A lot, in the same definitions, means the quantity of uniform material identified by the manufacturer as having been thoroughly mixed in a single vessel. A filling refers to a group of final containers identical in all respects which have been filled with the same product from the same bulk lot.

The sterility test, and the single repeat

The sterility section is the longest of the release standards and the most procedurally specific. Manufacturers must perform sterility testing of each lot of each product's final container material or other material, as appropriate and as approved in the licence application.

Three requirements govern the test itself. It must be appropriate to the material being tested, such that the material does not interfere with or otherwise hinder the test. It must be validated to demonstrate that it is capable of reliably and consistently detecting the presence of viable contaminating microorganisms. And it, together with its components, must be verified to demonstrate that the method can consistently detect that presence.

Written procedures must describe at minimum the test method — with, for culture-based methods, the composition of the culture media, growth-promotion test requirements and incubation conditions of time and temperature; and for non-culture-based methods, the composition of test components, the test parameters including acceptance criteria, and the controls used to verify the method's ability to detect viable organisms. They must also describe the sampling method including the number, volume and size of articles tested, and written specifications for accepting or rejecting each lot.

The sample itself must be appropriate to the material, considering at minimum the size and volume of the final product lot, the duration of manufacturing, the final container configuration and size, and the quantity or concentration of inhibitors, neutralisers and preservatives present.

Then comes the clause that decides what a sterility result means. If the initial test indicates the presence of microorganisms, the product does not comply — unless a thorough investigation by the quality control unit can ascribe the microbial presence definitively to a laboratory error or faulty materials used in conducting the testing.

Where that investigation reaches that conclusion, the test may be repeated one time. If no evidence of microorganisms is found in the repeat, the product complies. If evidence is found, it does not. A repeat must use the same test method as the initial test, and must be conducted with comparable product reflective of the initial sample in terms of sample location and the stage in the manufacturing process it came from. One repeat, on a stated basis, with a matched sample.

Purity, identity, and the test done after the labels go on

The purity section opens with a standard and then adds two tests. Products shall be free of extraneous material except that which is unavoidable in the manufacturing process described in the approved licence application.

The first test is for residual moisture. Each lot of dried product must be tested and must meet and not exceed established limits specified by an approved method on file in the licence application. The test may be exempted where the relevant centre director deems it unnecessary for the continued safety, purity and potency of the product.

The second is for pyrogenic substances, and it is a biological assay rather than a chemical one. Each lot of final containers of any product intended for use by injection must be tested for pyrogenic substances by intravenous injection into rabbits, subject to a list of excepted product categories. The test procedure follows a named pharmacopeial standard. If a lot fails, the test may be repeated once using five other rabbits, and the temperature rises recorded for all eight animals are included in determining whether the requirements are met.

The identity test is the one whose timing is the point. The contents of a final container of each filling of each lot must be tested for identity after all labelling operations have been completed.

That sequencing exists because the failure mode being guarded against is not chemical. The test must be specific for each product in a manner that will adequately identify it as the product designated on the final container and package labels and circulars, and distinguish it from any other product being processed in the same laboratory. Identity may be established through the physical or chemical characteristics of the product, inspection by macroscopic or microscopic methods, specific cultural tests, or in vitro or in vivo immunological tests. The question being answered is whether the label on this container matches what is inside it, and that question cannot be answered before the label is on.

What goes in besides the product, and who can release a lot

The constituent materials section governs everything in the container that is not the active substance. All ingredients used in a licensed product, and any diluent provided as an aid in administration, must meet generally accepted standards of purity and quality.

Preservatives carry two conditions rather than one. Any preservative used must be sufficiently nontoxic that the amount present in the recommended dose will not be toxic to the recipient. And, in the combination used, it must not denature the specific substances in the product so as to result in a decrease below the minimum acceptable potency within the dating period when stored at the recommended temperature. A preservative that protects against contamination while quietly degrading the product fails the second condition even though it passes the first.

Adjuvants are gated on evidence. An adjuvant may not be introduced into a product unless there is satisfactory evidence that it does not adversely affect the safety or potency of the product.

Changing a test method is similarly gated. Modification of any particular test method or manufacturing process, or of the conditions under which it is conducted, is permitted only where the applicant presents evidence — in a licence application or a supplement — demonstrating that the modification will provide assurances of safety, purity, potency and effectiveness equal to or greater than those provided by the specified method, and only where approval is received in writing from the relevant centre director.

Above all of it sits a power that is rarely used and worth knowing exists. Samples of any lot of any licensed product, together with the protocols showing the results of applicable tests, may at any time be required to be sent to the relevant centre director. On such notification, a manufacturer must not distribute a lot until it is released by that director. The rule constrains the power in the same sentence: such notification is not issued except when deemed necessary for the safety, purity or potency of the product.

That is the ceiling of the system. A regulator can, in a defined circumstance, take the release decision away from the manufacturer entirely, one lot at a time. Nothing comparable exists for a product outside this framework — which is the most useful thing a reader can take from the part.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 610.1 — Tests prior to release required for each lot, read in full for the bar on releasing a lot before conformity testing is complete, the requirement that each test be made after all processes that may affect compliance, and the narrow exception permitting a result to be disregarded only where the test is established invalid for causes unrelated to the product — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
2. 21 CFR 610.2 — Requests for samples and protocols; official release, read in full for the power to require samples and test protocols at any time, the bar on distributing a lot until officially released, and the limit that such notification issues only where deemed necessary for safety, purity or potency — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
3. 21 CFR 610.12 — Sterility, read in full for the per-lot testing requirement, the appropriateness, validation and verification requirements, the minimum contents of written sterility procedures for culture-based and non-culture-based methods, the sampling considerations, and the repeat-test rule permitting exactly one repeat following a definitive quality control unit investigation — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
4. 21 CFR 610.13 and 610.14 — Purity and Identity, read in full for the freedom-from-extraneous-material standard, the residual moisture test and its exemption route, the rabbit pyrogen test with its retest using five further animals and the eight-animal reading, and the requirement that the identity test be performed after all labelling operations are completed and distinguish the product from others processed in the same laboratory — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
5. 21 CFR 610.9, 610.10, 610.15 and 610.17 — Equivalent methods and processes, Potency, Constituent materials and Permissible combinations, read for the two conditions on modifying a test method or process, the requirement that potency tests be specifically designed per product, the two-part preservative condition and the evidence gate on adjuvants, and the bar on combining licensed products without a licence for the combination — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
6. 21 CFR 600.3 — Definitions, read for the definitions of standards, continued as applied to the dating period, safety, sterility, purity, potency, lot and filling — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026